Form 4 for SKYE Skye Bioscience, Inc.
Accepted 2026-08-07 17:37:52 ET · period of report 2026-08-07 · accession 0001628280-26-054941 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-08-07 17:37 | 2026-08-07 | SKYE | DHILLON PUNIT | CEO, Dir | A - Grant | $0.00 | +1.09M | 1.42M | +330% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-08-07 | A | A | 1,090,000 | $0.00 | 1,419,823 | D | — | — | (F1) Represents a restricted stock unit ("RSU") award that will vest on August 31, 2027 subject to (a) the Reporting Person's continued employment through such date or (b) the termination of the Reporting Person's employment by the Company for any reason other than For Cause, By Death or By Disability (each, as defined in the Reporting Person's Executive Employment Agreement), provided the Reporting Person executes and does not revoke the release agreement appended to the Reporting Person's Executive Employment Agreement. (F2) Each RSU represents a contingent right to receive one share of the Issuer's common stock. |